Some antibiotic combinations have a sound clinical purpose, but a fixed-dose combination without adequate evidence or regulatory approval can expose patients to avoidable risks. A 2018 report on a study of products sold in India said 75 of 118 antibiotic fixed-dose combinations examined were not approved. That historical finding raises important questions about safety and antibiotic stewardship; it does not show that every combination is harmful or that those products caused a measured increase in resistance.
What is a fixed-dose combination antibiotic?
A fixed-dose combination (FDC) puts two or more active ingredients into a single formulation, such as one tablet. It can make sense when the ingredients work together for a defined condition and the evidence supports using them at set doses. The number of ingredients alone does not determine whether a medicine is appropriate.
As an Amazon Associate I earn from qualifying purchases.
An “irrational” FDC is one whose ingredients, doses, or intended use lack a sufficient scientific and therapeutic rationale. The Indian Express’s July 4, 2026 explainer notes that some FDCs are evidence-based while others lack adequate scientific support. The relevant question is not simply whether a product combines drugs, but whether each ingredient contributes to a demonstrated benefit and whether the fixed doses fit the clinical need.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →What did the 2018 India study report?
Chemistry World reported on February 17, 2018, that a study by P. McGettigan and colleagues found 75 of 118 antibiotic FDCs sold in India were not approved. The report also said many of the combinations lacked publicly available safety and efficacy data. It cites a 2018 paper in the British Journal of Clinical Pharmacology (DOI: 10.1111/bcp.13503).
#1 Best Overall
This is a study-period finding reported in 2018, not a current count of unapproved products. Approval and legality apply to particular products and jurisdictions, and can change over time. Nor does the finding mean that all antibiotic combinations are illegal: some have accepted clinical uses, and the approval status of one product cannot establish the status of another.
How could unsupported combinations add to resistance?
Antibiotics create selection pressure: susceptible bacteria are more likely to be killed, while bacteria able to survive treatment can persist and multiply. Unnecessary or prolonged antibiotic exposure can therefore give resistant organisms more opportunity to spread. If an unsupported combination exposes bacteria to drugs without a proven added benefit, it may add to that pressure.
Rank #2
- Storey publishing
- Language: english
- Book - herbal antibiotics, 2nd edition: natural alternatives for treating drug-resistant bacteria
That is a plausible stewardship concern, not proof that the FDCs examined in 2018 caused a measured rise in antimicrobial resistance. Chemistry World quoted Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy, warning that bacteria can face “extraordinary selection pressure from two antibiotics.” The available reporting does not quantify a causal resistance effect for the specific formulations in the study.
Free tools Windows power users keep installed
One-click scans. No signup required.
In the same 2018 report, infectious-disease specialist Marc Mendelson said that most bacterial infections can be treated with one antibiotic and that a second is often redundant. That is an attributed view, not a rule for every infection: some combination regimens are clinically justified.
What other risks can an irrational FDC pose?
Reported concerns include avoidable exposure to one or more medicines, adverse effects, allergic reactions, and possible interactions. A fixed dose can also make it harder for a clinician to adjust one ingredient without changing the dose of the other. If the components have different dosing needs or schedules, combining them may be impractical for a particular patient or indication.
These are potential concerns, not evidence that every FDC causes harm. The risk depends on the specific ingredients, doses, patient, and clinical use. Allyson Pollock, a study co-author, told Chemistry World: “Patients are consuming medicines that are potentially harmful.” Her warning should be read in the context of the combinations and data discussed in that report, not as a claim that all combination medicines are dangerous.
Rank #4
What does later evidence say about antibiotic combinations in rural India?
A 2022 cross-sectional survey published in Antibiotics examined medicine availability among 196 informal providers in rural India. It reported that 21% of the surveyed providers stocked antibiotic combinations and 46% stocked combinations that the World Health Organization does not recommend. Those percentages describe the sampled providers, not the whole of India or the national market.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The study also described difficulties in measuring informal markets, including the lack of sampling frames and sales or patient records, as well as reluctance to disclose illegal sales. Its findings point to a concern in the surveyed settings, but should not be treated as a national prevalence estimate.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How should a specific antibiotic FDC be assessed?
A combination’s name or the fact that it contains multiple antibiotics is not enough to judge whether it is appropriate. For a specific product and use, the relevant questions include:
- Is the product approved for that use in the relevant jurisdiction?
- Is there evidence that each ingredient contributes to the intended treatment effect?
- Does the combination offer a clinical benefit over an appropriate alternative?
- Are the ingredients’ safety profiles and potential interactions acceptable together?
- Do the components’ dosing schedules fit together?
- Could the fixed dose prevent a clinician from adjusting one ingredient appropriately?
These considerations help distinguish a justified combination from one that adds exposure without a demonstrated benefit. They do not substitute for a product-specific review or a clinician’s judgment about an individual patient.
What is known about the current legal position in India?
The 2018 Chemistry World report described efforts by the Indian government to prohibit many combinations and said the ban was being litigated at the time. The Indian Express reported on July 4, 2026, that the government had banned 16 FDC drugs, including certain antibiotic combinations. That is secondary reporting; the official order and product list, as well as any later court rulings, are not established here. The Central Drugs Standard Control Organization’s public notices listing includes a September 5, 2026 notice on coordinated action against illegal manufacture and distribution of misbranded drugs, but that notice is not specific to antibiotic FDCs.
Consequently, neither the old study count nor a general report of a later ban determines the current legal status of an individual medicine. That status must be checked against the applicable official order and any relevant court proceedings.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
